In a letter to HRSA, ASN emphasized the need for separating the technology portion of the OPTN contract as a stand-alone contract, requiring OPTN contractors to have complete and accurate data, and the enforcement of separate governance boards.
Priority #2:TRANSFORM TRANSPLANT and increase access to donor kidneys. If patients understood the benefits of transplantation and the process involved, more would likely accept the opportunity and pursue transplant listing.
ASN applauds the U.S. Food and Drug Administration for amending the emergency use authorizations for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals, including kidney transplant recipients.
Investigators discovered that kidney failure symptoms tended to increase or remain unchanged between transplant evaluation and transplantation; however, three months after transplantation, 9 of 11 symptoms lessened.
This week, the Baylor College of Medicine became the first academic center and care provider to publicly announce its support for the changes included in Medicare’s proposed rule on Organ Procurement Organizations (OPOs) Conditions for Coverage: Revisions to the Outcome Measure Requirements for Organ Procurement Organizations – joining the American Society of Nephrology (ASN) in its support of the proposed rule. ASN expressed its support in a separate comment letter and made recommendations for improvement. (ASN’s comments and recommendations will be covered in Kidney News’ March edition.)